NYSE:CTST - CannTrust Stock Price, Forecast & News

CannTrust trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTST."

CannTrust is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for CannTrust.

8 equities research analysts have issued 1-year price objectives for CannTrust's stock. Their forecasts range from C$2.00 to C$7.00. On average, they expect CannTrust's stock price to reach C$4.50 in the next year. This suggests a possible upside of 294.7% from the stock's current price. View Analyst Price Targets for CannTrust.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CannTrust in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CannTrust.

News headlines about CTST stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CannTrust earned a news impact score of -2.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for CannTrust.

CannTrust saw a drop in short interest in the month of December. As of December 13th, there was short interest totalling 12,050,000 shares, a drop of 8.2% from the November 28th total of 13,120,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is presently 6.1 days. Approximately 10.1% of the company's stock are sold short. View CannTrust's Current Options Chain.

Some companies that are related to CannTrust include TherapeuticsMD (TXMD), AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF), Kura Oncology (KURA), Akero Therapeutics (AKRO), MacroGenics (MGNX), Prothena (PRTA), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Neoleukin Therapeutics (NLTX), Clovis Oncology (CLVS), Viking Therapeutics (VKTX), BioDelivery Sciences International (BDSI) and Molecular Templates (MTEM).

Based on aggregate information from My MarketBeat watchlists, some companies that other CannTrust investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Aphria (APHA), KushCo (KSHB), Cronos Group (CRON), Aurora Cannabis (ACB), OrganiGram (OGI), HEXO (HEXO), Nokia Oyj (NOK) and Aphria (APHA).

Shares of CTST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CTST stock can currently be purchased for approximately C$1.14.

CannTrust has a market capitalization of C$161.30 million and generates C$35.22 million in revenue each year. The company earns C$-10,460,000.00 in net income (profit) each year or C($0.11) on an earnings per share basis. CannTrust employs 576 workers across the globe.View Additional Information About CannTrust.

The official website for CannTrust is http://www.canntrust.ca/.

CannTrust's mailing address is 3280 LANGSTAFF ROAD UNIT 1, VAUGHAN A6, L4K 4Z8. The company can be reached via phone at 64-7872-2300 or via email at [email protected]